PFIZER INC PFE
Pharmaceutical Preparations · NYSE
Umsatz
$73.64B
+80.0% Jahresübergangsrate
Nettoerlös
$2.12B
-93.2% Jahresübergangsrate
Gesamtvermögen
$213.40B
-5.8% Jahresübergangsrate
EPS
0.37
-93.2% Jahresübergangsrate
Nettomarge 2.9%
Einsendungen
Advertisement
Einkommensrechnung
| Zeitraum | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenues | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| SG&A Expense | $6.45B | $3.03B | $14.77B | $10.46B | $7.21B | $3.50B | $13.68B | $10.20B |
| Interest Expense | $1.31B | $654.00M | $2.21B | $2.35B | $1.57B | $790.00M | $1.24B | $1.52B |
| Net Income (Loss) | $5.88B | $2.97B | $2.12B | $7.62B | $3.16B | $3.12B | $31.37B | $5.49B |
| EPS (Diluted) | 1.03 | 0.52 | 0.37 | 1.34 | 0.55 | 0.55 | 5.47 | 0.96 |
Bilanz
| Zeitraum | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $208.16B | $208.16B | $213.40B | $213.40B | $213.40B | $213.40B | $226.50B | $226.50B |
| Current Assets | $42.90B | $42.90B | $50.36B | $50.36B | $50.36B | $50.36B | $43.33B | $43.33B |
| Cash & Equivalents | $1.14B | $1.14B | $1.04B | $1.04B | $1.04B | $1.04B | $2.85B | $2.85B |
| Accounts Receivable | $11.87B | $11.87B | $11.46B | $11.46B | $11.46B | $11.46B | $11.57B | $11.57B |
| Inventory | $10.65B | $10.65B | $10.85B | $10.85B | $10.85B | $10.85B | $10.19B | $10.19B |
| PP&E (Net) | $19.32B | $19.32B | $18.39B | $18.39B | $18.39B | $18.39B | $18.94B | $18.94B |
| Goodwill | $71.26B | $71.26B | $67.78B | $68.53B | $68.53B | $68.53B | $51.38B | $67.78B |
| Total Liabilities | $121.39B | $121.39B | $124.90B | $124.90B | $124.90B | $124.90B | $137.21B | $137.21B |
| Current Liabilities | $36.98B | $36.98B | $42.99B | $42.99B | $42.99B | $42.99B | $47.79B | $47.79B |
| Accounts Payable | $5.24B | $5.24B | $5.63B | $5.63B | $5.63B | $5.63B | $6.71B | $6.71B |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Stockholders Equity | $86.48B | $86.48B | $88.20B | $88.20B | $88.20B | $88.20B | $89.01B | $89.01B |
Kassenfluss
| Zeitraum | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.75B | $2.33B | $8.70B | $6.02B | $-691.00M | $1.09B | $29.27B | $3.46B |
| Investing Cash Flow | $7.22B | $3.27B | $-32.28B | $4.28B | $6.33B | $1.73B | $-15.78B | $-21.28B |
| Financing Cash Flow | $-8.42B | $-5.23B | $26.07B | $-12.03B | $-7.39B | $-4.93B | $-14.83B | $20.62B |
| Stock Repurchases | — | — | — | — | — | — | $2.00B | — |
Ähnliche Firmen
AbbVie Inc.
ABBV
ABBOTT LABORATORIES
ABT
BRISTOL MYERS SQUIBB CO
BMY
JOHNSON & JOHNSON
JNJ
ELI LILLY & Co
LLY
Merck & Co., Inc.
MRK
REGENERON PHARMACEUTICALS, INC.
REGN
VERTEX PHARMACEUTICALS INC / MA
VRTX
Mehr erfahren
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Daten stammen aus der öffentlichen Datenbank des US-amerikanischen SEC EDGAR. Diese Seite bietet keine Anlageberatung.